Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04193904 · ClinicalTrials.gov registry record · Phase 1
A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer
A Phase 1 study, sponsored by 4D pharma.
- Terminated
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT04193904: Clinical Trial Phase 1 study, sponsored by 4D pharma.
NCT04193904 is a Phase 1 study that was terminated before completion, run by 4D pharma. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04193904, a Phase 1 study, was terminated before completion, sponsored by 4D pharma.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a single center, open-label, phase I study to evaluate the safety and preliminary efficacy of MRx0518 with preoperative hypofractionated radiation in 15 patients with resectable pancreatic cancer. Subjects will take MRx0518 daily for one week prior to the start of radiation therapy, throughout radiation and until surgical resection of the tumour.
Primary Outcome
Adverse events will be assessed as per CTCAE v5.0
Interventions
- DRUG MRx0518
- RADIATION Hypofractionated Preoperative Radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-12-20 |
| Est. Completion | 2023-05-08 |
| Phase | Phase 1 |
Why NCT04193904 stopped before completion
NCT04193904 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 2 interventions - of which MRx0518 is the first listed.
NCT04193904 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04193904 about?
NCT04193904 is a clinical study titled "A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer". This is a single center, open-label, phase I study to evaluate the safety and preliminary efficacy of MRx0518 with preoperative hypofractionated radiation in 15 patients with resectable pancreatic cancer. Subjects will take MRx0518 daily for one week prior to the start of radiation therapy, through...
What is the current status of trial NCT04193904?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2019-12-20. Estimated completion is 2023-05-08.
What interventions are being tested in trial NCT04193904?
The interventions under investigation include: MRx0518 (DRUG), Hypofractionated Preoperative Radiation (RADIATION).
Who is sponsoring clinical trial NCT04193904?
This trial is sponsored by 4D pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04193904's enrollment target sits among peer trials
13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI